24 jul: Bobler fra dybet fik hammerslag på rekordpriser ved nyligt afhold..
01 aug: Mercedes CLS Shooting Brake på vej til Danmark
31-07-2012 12:55:00

U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH

Relateret indhold

Among the companies with shares expected to actively trade in Tuesday's session are Seagate Technology Inc. (STX), Humana Inc. (HUM) and Dendreon Corp. (DNDN).

Seagate reported record fiscal fourth-quarter revenue but tempered its sales growth expectations for the calendar year as demand softens and hard-disk drive rivals recover faster than anticipated from severe Asian flooding. Shares of the company fell 7.7% to $28.08 after hours.

Humana reported weaker second-quarter earnings, pressured by a recent legal settlement, while cutting its full-year forecast because of high costs for both new and existing customers on Medicare plans. Shares were off 8.9% to $64.30 after hours.

Dendreon unveiled restructuring plans that include cutting more than 600 jobs over the next year as the pharmaceutical company continues to lose money due to slow sales of its prostate-cancer treatment. Shares of the company sank 19% to $4.98 in after-hours trading.

Revenue-manager Accretive Health Inc. (AH) said it reached a $2.5 million settlement with the Minnesota Attorney General's office over an ongoing lawsuit and said it voluntarily decided to cease all its operations in Minnesota. Shares climbed 22% to $12.25 after hours.

CafePress Inc.'s (PRSS) second-quarter loss widened on higher marketing costs and the e-commerce company offered a downbeat outlook for the second half of the year. Shares dove 37% to $8.65 after hours.

Cirrus Logic Inc.'s (CRUS) fiscal first-quarter income dropped 25% as the chip maker saw higher expenses mask stronger revenue, bolstered by growth in its audio products segments. But shares jumped 20% after hours to $35.66 after the company predicted strongly upbeat fiscal third-quarter revenue and narrowly beat earnings expectations for the latest period.

Fiserv Inc.'s (FISV) second-quarter earnings increased 79% as a loss from early debt extinguishment weighed on the financial technology provider's year-ago results and as revenue increased. Shares were up 3.8% to $75 after-hours as adjusted profits beat analyst expectations.

Forest Oil Corp. (FST) swung to an unexpected loss in the second quarter amid a ceiling test write-down related to low natural-gas prices as the exploration-and-production company was also hurt by lower revenue. Shares slipped 9.4% to $6.40 after hours.

Herbalife Ltd.'s (HLF) second-quarter profit rose 20% as the nutrition company saw broad-based growth in sales volume. The company also raised its full-year earnings outlook. Shares were up 6% to $54.79 after hours.

Masco Corp. (MAS) swung to a second-quarter loss, as a large litigation settlement charge weighed down the period. Shares slumped 8.8% to $11.97 after hours.

Natural-gas exploration company McMoRan Exploration Co. (MMR) said it will delay a flow test previously scheduled for this week at its Davy Jones No. 1 well until a later date sometime in August, saying a seal assembly located at about 16,400 feet needed to be replaced. Shares slid 9.2% to $12.54 after hours.

PMC-Sierra Inc.'s (PMCS) second-quarter profit rose 58% as a recovery of income taxes boosted the chip maker's bottom line, though revenue and adjusted profits slipped from a year earlier. Shares were down 9.4% to $5.42 after hours as the company issued downbeat guidance for the current quarter.

RealD Inc.'s (RLD) fiscal first-quarter income fell 69% as the 3-D technology company's margins suffered on higher licensing and product costs. Shares plummeted 20% to $10.11 in after-hours trading as results missed analyst expectations.

Regeneron Pharmaceuticals Inc. (REGN) said the U.S. Food and Drug Administration didn't approve its Arcalyst drug as a treatment for gout and said the agency needs additional clinical data. Shares ....

Rudolph Technologies Inc.'s (RTEC) second-quarter earnings fell 8.8% as it recorded a larger income-tax provision, but the results of the provider of process characterization equipment beat its own expectations. Shares increased 15% to $9.70 after hours.

Superior Energy Services Inc.'s (SPN) second-quarter earnings soared as revenue of the provider of oil-field services more than doubled. But shares slipped 9.1% to $21.20 after hours as the company lowered its full-year earnings guidance, noting continued low natural-gas prices as well as declines in realized crude oil and liquids prices are impacting customers' cash flows, leading to reduced spending in the second half of the year.

Vertex Pharmaceuticals Inc.'s (VRTX) second-quarter loss narrowed on growing revenue from a hepatitis C drug, and the drug company reported positive results from a study on another experimental treatment for the disease. Shares were up 6.9% at $53.42 in after-hours trading.

Watchlist:

Anadarko Petroleum Corp. (APC) swung to a loss in the second quarter as the oil-exploration company was hurt by a $978 million write-down related mostly to coalbed-methane properties at a time of low natural-gas prices.

Eastman Chemical Co.'s (EMN) second-quarter earnings fell 19% as the chemical-and-materials maker reported acquisition costs and weaker revenue in several of its businesses.

Flowserve Corp.'s (FLS) second-quarter earnings rose a better-than-expected 8.7% as the valve-and-pump maker reported improved sales in all three major segments, led by its engineered-product division.

Hertz Global Holdings Inc.'s (HTZ) second-quarter profit jumped 69% due to stronger sales for car and equipment rentals, while higher volume and cost-control initiatives also helped bolster the bottom line.

Hologic Inc.'s (HOLX) fiscal third-quarter earnings fell 35% as the health-products company was hit by higher acquisition-related charges and other items. However, adjusted earnings improved.

PartnerRe Ltd.'s (PRE) second-quarter profit rose 42% as the reinsurer logged fewer expenses and saw growth in premiums written.

Plum Creek Timber Co.'s (PCL) second-quarter earnings fell 18% as the real-estate investment trust saw higher costs outpace improved revenue.

Post Properties Inc.'s (PPS) second-quarter earnings more than doubled as the real-estate investment trust's occupancy and rents strengthened. The company again raised its full-year view for funds from operations.

-Write to Nathalie Tadena at nathalie.tadena@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 31, 2012 06:55 ET (10:55 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/tendens: Genmab og Vestas fortsætter i fokus

13-12-2017 08:18:09
Aktier som Genmab og Vestas kan fortsætte med at være i fokus onsdag efter fald i de to aktier i tirsdagens handel, men overordnet kan markedet blive præget af afventende investorer forud for resultatet af rentemødet i den amerikanske centralbank onsdag aften.Siden dansk børslukketid tirsdag har der været markedsmæssig fokus på senatsvalget i staten Alabama, hvor demokraten Doug Jones vandt og ind..

Vestas/Sydbank: Glem det sædvanlige amerikanske ordrerus i julen

12-12-2017 15:57:15
De seneste år har Vestas halet den ene amerikanske ordre ind efter den anden i juletiden og frem mod nytåret, men det skal man ikke forvente i samme omfang i år, efter at der er kommet usikkerhed om de fremtidige rammebetingelser for opførelse af vindprojekter i USA.Det siger aktieanalysechef Jacob Pedersen fra Sydbank til Ritzau Finans.Det er præsident Trumps skattereform, der har vendt op og ned..

Genmab/IR: Royalties vil som minimum dække omkostningerne næste år

12-12-2017 14:04:43
Genmabs royaltyindtægter fra salget af selskabets kræftmidler vil i 2018 som minimum dække omkostningerne.Det præciserer Genmabs IR- og kommunikationsdirektør, Rachel Curtis Gravesen, i en e-mail over for Ritzau Finans, efter at selskabet i nattens løb er kommet med en foreløbig prognose for 2018, som angiveligt har givet anledning til en del tolkning i analytikerkredse vedrørende salget af Genmab..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas/Sydbank: Glem det sædvanlige amerikanske ordrerus i julen
2
Aktier/tendens: Genmab og Vestas fortsætter i fokus
3
Genmab/IR: Royalties vil som minimum dække omkostningerne næste år
4
Genmab-aktien får kurstæsk efter forsigtig udmelding fra ledelsen - NY
5
Tirsdagens aktier: Genmab og Vestas holdt C20 i kort snor

Relaterede aktiekurser

Anadarko Petroleum Corpo.. 48,54 0,0% Aktiekurs uændret
Eastman Chemical Company 93,02 0,0% Aktiekurs uændret
Flowserve Corporation 41,26 0,0% Aktiekurs uændret
Humana Inc 254,54 0,0% Aktiekurs uændret
Masco Corporation 42,19 0,0% Aktiekurs uændret
Cirrus Logic Inc 50,39 0,0% Aktiekurs uændret
Fiserv Inc 131,20 0,0% Aktiekurs uændret
Hologic Inc 43,58 0,0% Aktiekurs uændret
Regeneron Pharmaceutical.. 381,72 0,0% Aktiekurs uændret
Vertex Pharmaceuticals I.. 140,91 0,0% Aktiekurs uændret
Superior Energy Services.. 9,40 0,0% Aktiekurs uændret
Hertz Global Holdings In.. 21,70 0,0% Aktiekurs uændret
Seagate Technology PLC -.. 42,12 0,0% Aktiekurs uændret
Herbalife Ltd 69,97 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
13. december 2017 10:13:43
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB7 - 2017-12-13 10:13:43 - 2017-12-13 10:13:43 - 1 - Website: OKAY